Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-11
2006-04-11
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S325000
Reexamination Certificate
active
07026299
ABSTRACT:
The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
REFERENCES:
patent: 5408040 (1995-04-01), Grotendorst et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5837258 (1998-11-01), Grotendorst
patent: 5944710 (1999-08-01), Dev et al.
patent: 6051424 (2000-04-01), Kato et al.
patent: 6069006 (2000-05-01), Grotendorst et al.
patent: 0495674 (1992-07-01), None
patent: WO-88/03409 (1988-05-01), None
patent: WO-89/08667 (1989-09-01), None
patent: WO-94/03599 (1994-02-01), None
patent: WO 97/33995 (1997-03-01), None
patent: WO-97/33995 (1997-09-01), None
patent: WO-00/35939 (2000-06-01), None
Anderson, W.F. Human Gene Therapy. Nature, 1998 vol. 392(6679 Suppl):25-30.
Anderson, W.F. The Current Status of Clinical Gene Therapy. Human Gene Therapy, 2002 vol. 13:1261-1262.
Crystal, R. Transfer of Genes to HUmans: EArly Lessons and Obstacles to Success. Science, 1995 vol. 270:404-410.
Brach, A. A Good Antisense Moleculer is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Babic et al. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci., 1998 vol. 95:6355-6360.
Xie et al., “CRY61, an angiogenic inducer, is over-expressed and estrogen inducible in breast cancer.” Proceedings of 91st Annual Meeting for Amer. Assoc. for Cancer Res., vol. 41 (Apr. 1, 2000).
Babic et al., “Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavabeta3, promotes endothelial cell survival, and induces angiogenesis in vivo.” Mol Cell Biol. Apr. 1999;19(4):2958-66.
Jedsadayanmata et al., “Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(llb)beta(3).” J Biol Chem. Aug. 20, 1999;274(34):24321-7.
Shimo et al., “Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells.” J. Biochemistry v. 124(1) p. 130-140 (Jul. 1998).
Pakkanen et al., “Gene Therapy for Atherosclerosis and Atherosclerosis-Related Disease,”Current Atherosclerosis Rep., 1:123-130 (1999).
Diaz-Sandoval et al., “Gene therapy for cardiovascular angiogenesis,”Expert Opin. Biol. Ther., 3(4):599-616 (2003).
Nikol et al., “Vasular Gene Therapy—Preclinical and Clinical Experience in Vascular Gene Therapy: Advantages Over Conservative/Standard Therapy,”J. Invas. Cardiol., 13:333-338 (2001).
Geneseq Accession No. AAT97142, Toyobo, K.K., “Human monocyte mature differentiation factor encoding cDNA” (Mar. 5, 1998).
Geneseq Accession No. AAW35957, Toyobo, K.K., “A monocyte mature differentiation factor—useful for the long term tissue culture of macrophage(s)” (Mar. 5, 1998).
Geneseq Accession No. AAT94699, Lau, L.F., “Human cysteine rich protein 61 (Cyr61) cDNA” (Mar. 27, 1998).
Geneseq Accession No. AAW35730, Lau, L.F., “Human cysteine rich protein 61 (Cyr61)” (Mar. 27, 1998).
International Search Report for PCT/US01/21799.
Latinkic et al., “Promoter function and structure of the growth factor-inducible immediate early gene cyr61,”Nucleic Acids Research, 19(12):3261-3267 (1991).
O'Brien et al., “Expression of cry61, a Growth Factor-Inducible Immediate-Early Gene,”Molec. and Cell. Biol., 10(7):3569-3577 (Jul. 1990).
Simmons et al.,“Identification of a phorbol ester-repressible v-src-inducible gene.”PNAS, USA, 86:1178-1182 (1989).
Oemar et al., “Molecular cloning and expression of human connective tissue growth factor,”Hypertension, 22(3):424 (1993).
Oemar et al.,“Expression of recombinant human connective tissue growth factor in insect cells,”European Heart Journal, 15(Abstr. Suppl.):486 (1994).
Bradham et al.,“Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10,”J. Cell Biol., 114(6):1285-1294 (1991).
George et al., “Current methods in sequence comparison and analysis,” inMacromolecular Sequencing and Synthesis, Selected Methods and Applications, D.H. Schlesinger (ed.), Alan R. Liss, Inc., New York, NY, pp. 127-149 (1988).
Boswell et al., “Sequence Comparison and alignemnt: the measurement and interpretation of sequence similarity,” inComputational Molecular Biology: Sources and Methods for Sequence Analysis, Arthur M. Lesk (ed.), Oxford University Press, New York, NY, pp. 161-178 (1988).
O'Brien et al., “Expression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic development,” inCell Growth Differe., 3(9):6645-654 (Sep. 1992).
GeneSeq Accession No. Q26421, Brunner, A.M., “TGF-beta induced gene family—encodes proteins involved in growth and differentitation effects of TGF-beta-1” (Jan. 18, 1993).
GeneSeq Accession No. Q26422, Brunner, A.M., “TGF-beta induced gene family—encodes proteins involved in growth and differentiation effects of TGF-beta-1” (Jan. 18, 1993).
GeneSeq Accession No. R25565, Brunner, A.M., “TGF-beta induced gene family—encodes proteins involved in growth and differentiation effects of TGF-beta-1” (Jan. 18, 1993).
GeneSeq Accession No. R25566, Brunner, A.M., “TGF-beta induced gene family—encodes proteins involved in growth and differentiation effects of TGF-beta-1” (Jan. 18, 1993).
GeneSeq Accession No. R46078, Iwahori, A., “cDNA of human origin and proteins coded by it—which may be expressed by in vivo or in vitro translation using sense RNA or antisense DNA corresponding to the cDNA” (Oct. 19, 1994).
GeneSeq Accession No. Q57417, Iwahori, A., “cDNA of human origin and proteins coded by it—which may be expressed by in vivo or in vitro translation using sense RNA or antisense DNA corresponding to the cDNA” (Jan. 19, 1994).
Adams Mark D.
Calenda Valérie
Fataccioli Virginie
Li Haodong
Gibbs Terra C.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Transgene S.A.
Wang Andrew
LandOfFree
Connective tissue growth factor-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Connective tissue growth factor-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Connective tissue growth factor-2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549202